We have addressed the following drug issues
- Actos (pioglitazone hydrochloride)
- Adoair Diskus（fulticasone propionate/salmeterol xinafoate dry-powder inhaler）
- Albumin (human serum albumin)
- Arava (leflunomide)
- Berotec Aerosol (fenoterol hydrobromide)
- BSE
- Cerebral Metabolic Enhancers
- Champix (varenicline tartrate)
- cholesterol reducers,antihyperlipemics
- Dormicum (midazolam)
- Drug Eluting Stent (DES)
- Enbrel (Etanercept)
- EVAHEART
- Fluoride Mouth Rinsing Program
- Gatiflo (gatifloxacin hydrate)
- H2-receptor antagonist
- Halcion (triazolam)
- Idamycin (idarubicin hydrochloride)
- Influenza HA Vaccine
- Iressa (Gefitinib)
- Mylis (sodium prasterone sulfate)
- Noscal (troglitazone)
- Panaldine (ticlopidine hydrochloride)
- pharmaceutical additives, especially butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT)
- PPA: phenylpropanolamine hydrochloride
- Protopic Ointment (tacrolimus hydrate)
- Radicut (edaravone)
- Seirogan (wood creosote)
- SSRI - Paxil etc)
- Tamiflu (oseltamivir phosphate)
- Tap water Fluoridation
- Thalidomide
- Triludan (terfenadine)
- Zithromac (azithromycin hydrate)
We have addressed the following regulatory system issues
- Act on Protection of Patients Subject to Clinical Tests
- Advertisement of Recruiting Examinees
- Clinical Trials Registration System
- Conflict of interests
- Disclosure of the Reports of Side Effects of Seirogan (creosote)
- Educational Video Produced by the JPMA
- Freedom-of-information requests regarding the minutes of pharmaceutical committees at hospitals
- Guidelines on Interaction
- New Drug Application (NDA) system that accepted only published data in applications for drug licensing
- PPA:phenylpropanolamine hydrochloride
- Regulation on OTC Drugs Online Selling
- Regulation Restricting Employment from Pharmaceutical Industries of the Employment in PMDA
- Revision of Guidelines on the Clinical Evaluation Method of Anti-malignant Tumor Medicine
- The PMDA (Pharmaceuticals and Medical Devices Agency) Act
- The Public Comment System
